Linked research, clinical, and regulatory source pathways.
Company profile
About CellaVision
CellaVision is a world-leading provider of digital hematology microscopy solutions that automate and transform the process of performing blood differentials for laboratories of all sizes. Founded over 30 years ago and headquartered in Lund, Sweden, the company has sold more than 9,500 units across over 40 countries. CellaVision's comprehensive portfolio includes advanced digital cell morphology analyzers, software applications, reagents, and staining systems that enable laboratories to automate, standardize, and simplify morphological examination of blood and body fluid samples. The company's technology replaces manual microscopy with automated digital imaging systems that improve efficiency, connectivity, and proficiency while minimizing human error. CellaVision serves both human and veterinary hematology laboratories, offering scalable solutions adapted to customer needs regarding analysis capacity, sample preparation, data centralization, and workflow monitoring. With 250 employees globally and market support offices in 13 markets, CellaVision manufactures analyzers through outsourced production in Sweden while performing in-house stain manufacturing in Bordeaux, France. The company's solutions cover peripheral blood analysis, bone marrow aspirate examination, body fluid analysis, and advanced RBC applications, supported by proficiency software for training and competency development.
Company description CellaVision official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at CellaVision?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- blood cell abnormalities
- body fluid analysis
- bone marrow conditions
- hematology disorders
Who it serves
- hematology laboratories
- hospital laboratories
- multi-site laboratory networks
- reference laboratories
- veterinary laboratories
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsBrazil · China · France · Germany · Global · Italy · Japan · over 40 countries · Portugal · Spain · Sweden · United Arab Emirates
Company sourceOfficial website
Company milestones
Platform expansion
Launch of Digital Cell Morphology Software 7.2 (largest software update); Launch of Bone Marrow Aspirate Application in EMEA region (2026)
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Risk Assessment of Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Infected Patients Using Laboratory Data and Immune Cell Morphologic Assessment.Archives of pathology & laboratory medicine · Jan 1, 2022
Smudge Cells in Chronic Lymphocytic Leukemia: Pathophysiology, Laboratory Considerations, and Clinical Significance.Laboratory medicine · Sep 1, 2021
Digital morphology analyzers in hematology: Comments on the ICSH review and recommendations.International journal of laboratory hematology · Oct 1, 2020
Comparison of Different Small Clinical Hematology Laboratory Configurations With Focus on Remote Smear Imaging.Archives of pathology & laboratory medicine · Oct 1, 2019
Impact of Integrating Rumke Statistics to Assist with Choosing Between Automated Hematology Analyzer Differentials vs Manual Differentials.The journal of applied laboratory medicine · Jan 1, 2017
Performance evaluation of the automated morphological analysis of erythrocytes by CellaVision DM96.Clinical laboratory · Jan 1, 2013
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
CellaVision DC-1, CellaVision DC-1 PPAK200595 · 510k · Oct 16, 2020
CELLAVISION DM1200 WITH THE BODY FLUID APPLICTIONK102778 · 510k · Sep 16, 2011
CELLAVISION DM96 WITH THE BODY FLUID APPLICATIONK080595 · 510k · Dec 5, 2008
CELLAVISION DM96 AUTOMATIC HEMATOLOGY ANALYZERK033840 · 510k · Feb 10, 2004
DIFFMASTER OCTAVIA AUTOMATIC HEMATOLOGY ANALYZERK003301 · 510k · Mar 15, 2001
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
efficiency improvement
replacing manual microscopy with automated digital imaging that saves time and releases skilled staff
error reduction
minimizing human error through automation and standardization
workflow consistency
standardizing processes across multi-site laboratory networks
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from CellaVision
Recent articles published on CellaVision's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.